AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aquestive Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.83+0.05 (+1.32%)

Close on Oct 19, 2026

Market cap: $478.73M
P/E (TTM): –
Dividend yield: –

Aquestive Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	121	72	24	27	28	32	49	61	17	9.21
Cash & Short-Term Investments	121	72	24	27	28	32	49	61	17	9.21
Receivables	18	7.34	8.47	–	–	–	–	6.48	6.18	–
Inventory	6.17	6.04	6.77	5.78	4.04	2.46	2.86	5.44	4.01	–
Prepaid Expenses & Other	4.17	3.29	1.85	2.13	3.08	3.40	3.00	1.68	0.59	–
Total Current Assets	149	88	41	40	47	45	68	74	28	–
Property, Plant & Equipment	3.89	3.80	4.18	4.09	5.06	6.87	9.73	12	13	–
Gross Property, Plant & Equipment	48	47	47	46	45	48	48	47	45	–
Accumulated Depreciation	-44	-44	-43	-42	-40	-41	-38	-35	-32	–
Operating Lease Right-of-Use Assets	4.62	5.18	5.56	5.21	2.73	3.45	0	–	–	–
Intangible Assets	0	0	1.28	1.44	0.05	0.10	0.15	0.20	0.25	–
Other Long-Term Assets	2.64	4.22	5.44	6.45	6.90	7.84	0.29	0.24	1.24	–
Total Assets	160	101	57	57	62	63	78	87	43	–
Accounts Payable	30	10	8.93	9.95	8.31	7.09	12	20	9.60	–
Accrued Expenses	5.03	5.91	6.50	7.97	8.74	8.57	5.48	7.20	4.40	–
Current Debt	9.99	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.63	0.51	0.39	0.26	0.90	0.73	0	–	–	–
Current Income Taxes Payable	0.35	0.37	0.34	0.32	0.35	0.32	0.30	0.39	0.37	–
Deferred Revenue (Current)	1.09	1.05	1.55	1.51	0.77	0.69	0.81	0.72	–	–
Total Current Liabilities	48	19	18	40	22	21	19	33	15	–
Long-Term Debt	28	33	28	33	–	–	–	–	–	–
Long-Term Leases	4.34	4.97	5.40	5.09	1.95	2.85	0	–	–	–
Operating Lease Liabilities	4.97	5.48	5.81	5.34	2.85	3.57	0	–	–	–
Other Long-Term Liabilities	7.27	2.40	2.02	2.03	2.49	1.95	1.36	–	–	–
Total Liabilities	194	162	164	176	144	111	85	77	70	–
Total Debt	38	33	28	33	–	–	–	–	–	–
Common Stock	0.12	0.09	0.07	0.06	0.04	0.04	0.03	0.03	0	–
Additional Paid-In Capital	413	303	213	193	175	138	124	71	0	–
Retained Earnings	-447	-363	-319	-311	-257	-186	-130	-61	-120	–
Shareholders' Equity	-34	-60	-106	-119	-82	-48	-6.12	10	-26	-57
Total Equity	-34	-60	-106	-119	-82	-48	-6.12	10	-26	-57
Total Liabilities & Equity	160	101	57	57	62	63	78	87	43	–
Shares Outstanding(shares)	122	91	69	55	41	35	34	25	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 67.0%
Operating margin: -97.5%
Net margin: -144.6%
Return on equity, FY2025: 178.6%

Financial strength

Current ratio: 7.19
Debt to equity: -0.90
Debt to assets: 38.4%
Cash to current liabilities: 597.7%

Valuation

P/E ratio: –
Price to sales: 8.85
Price to book: –
Dividend yield: –